Theranexus's Novel Combo Disappoints In Narcolepsy
The French biotech’s lead drug candidate has suffered a clinical-stage setback in narcolepsy, but the Paris-quoted firm is hoping that a Parkinson’s study will give more traction to its pipeline of CNS disease candidates.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.
While other large biopharma companies are withdrawing from CNS research, Biogen is rare in not only staying in, but doubling down. Executives at the company’s 40th anniversary event in Switzerland explained why.